Promiscuous drug mechanisms in obesity, diabetes, and NASH; using proteomics to compare benefits across multiple organ systems
What factors contribute to successful weight loss?
Non-invasive diagnosis and assessment of NASH in real world clinical practice
Fully automated NASH quantification using Deep Learning Applications
Machine Learning in NAFLD
Plasma TREM2 as a potential novel non-invasive NASH biomarker
Recent insights in the pathophysiology and treatment of pediatric NAFLD
Nonalcoholic steatohepatitis (NASH) is a serious, progressive disease
Advancement in Therapeutics: Anti-Obesity Medications
Exercise as medicine for patients with NAFLD
The relationship between type 2 diabetes and NAFLD and relevant treatments for NAFLD
Advancement of rencofilstat in NASH phase 2 – evaluating both structural and functional data
Lanifibranor, a balanced pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH
Administration of glutaredoxin in hepatocytes is a potential therapeutic against NASH progression
Humans as the model: human fatty liver perfusion to bypass poorly predictive animal models
Vascular alterations in NASH and NASH cirrhosis
The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm
Innovating in NASH cirrhosis
Getting GRIP on NASH: Implementation of an International Clinical Screening Program
Systematic evaluation of non-invasive imaging and serum-based tests for detecting NAFLD
Integrating Metabolomics into NASH R and D
CRV431 Clinical Plans in NASH
Validation and comparison of the diagnostic, performance of HepaFat-Scan® for assessment of liver steatosis by MRI
Bariatric surgery in NASH: benefits and pitfalls
Treating NASH through a unique mode of action with tesamorelin
Histological scoring systems from the pathologist point of viewource Title
Safety and Efficacy of CRV431 in NASH: A Quantitative Systems Pharmacology Analysis
Drug Development for NASH with Fibrosis: A Regulatory Perspective
Challenges of assessing efficacy of drugs in NASH treatment
Prebiotic xylo-oligosaccharides (XOS) ameliorate non-alcoholic fatty liver disease (NAFLD)esource Title
Inhibiting NOX enzymes to treat mulitple diseases with high medical need
The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
Genetics of progressive NAFLD
Webinars
NASH: Accelerating awareness, identification and clinical trial enrolment
Podcasts
Wrapping Up Day Two Of The Fourth Global NASH Congress — Drugs, Lifestyles and Health Policy
Day Two At The 4th Global NASH Congress — Many New Drugs and Non-Pharmacologic Interventions
Day One At The 4th Global NASH Congress — Diagnostics, Drugs And Regulatory Issues
Pharmacotherapy Themes At The 4th Global NASH Congress
Patient-Centric Themes At The 4th Global NASH Congress
Non-Invasive Testing Themes At The 4th global NASH Congress
Previewing the 4th Global NASH congress
Poster Presentations
Development of a diet-induced disease-mimicking in vitro model of non-alcoholic steatohepatitis / fibrosis
Presentation Slides
A biomarker of fibrosis resolution, CTX-III, increases after bariatric surgery in early NAFLD patients with histological liver improvements
Thioacrylamide-derivatives with hepato-protective and anti-fibrotic activity
Targeting different pathways of NASH pathogenesis using single and combination therapies
Modulation of the mitochondrial pyruvate carrier (MPC) as a treatment for NASH
Body composition in NASH clinical trials
Liver biopsy as the gold standard for diagnosis
FDA Regulatory considerations for NASH clinical trial endpoints
Imaging based technologies for NAFLD in clinical practice
GKT831: A novel PII anti-fibrotic small molecule
The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
Genetics of progressive nonalcoholic fatty liver disease
Application of non-invasive tests for liver fibrosis
Discovery and validation of protein signatures for NAFLD risk and NASH status
The Poxel NASH portfolio: PXL770 and PXL065 two Differentiated Drug Candidates with Complementary Mechanisms of Action for the Treatment of NASH
Dual GLP-1 Agonists in the Treatment Metabolic & Liver Dysfunction in NASH
Multiparametric MRI for the evaluation of NAFLD
Sustained FXR agonist as optimized, best-in-class treatment for NASH
Identifying patients with risk of adverse outcomes – where should we look more closely?
The role of lysosomal acid lipase activity in NAFLD/NASH pathogenesis
NASH Trial Recruitment: The AES Solution
RNAi strategy for the treatment of NASH: focus on astrocyte elevated Gene-1 (AEG-1)
Metabolic changes and biomarkers preceding and associated with NASH
How the gut talks to the brain to impact the liver
Diabetes and NAFLD: a vicious spiral affecting both diseases
The impact of medical devices on diabetes and fatty liver disease
Resmetirom, a highly beta selective liver-directed thyroid hormone receptor beta agonist for the treatment of NASH
Endpoint Adjudication Best Practices for NASH trials
We are using cookies to give you the best experience on our site. By continuing to use our website you are agreeing to our use of cookies.AcceptRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.